Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. NAMS.NASDAQ

NewAmsterdam Pharma Company N.V. (NAMS NASDAQ) stock market data APIs

$18.75 -0.11(-0.6%) as of July 26, 2024
Price chart is built with Anychart

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V. Financial Data Overview

18.86
18.75
-
18.9639
18.7
5.633-26.35
1 685 M
89 986 K
6 862 K
-1.061
0.011
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NAMS',
Type: 'Common Stock',
Name: 'NewAmsterdam Pharma Company N.V.',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG01BNNTQN4',
ISIN: NULL,
CUSIP: NULL,
CIK: '1936258',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2022-11-23',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

NewAmsterdam Pharma Company N.V. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 6 862 K
  • EBITDA -198 540 992
  • Earnings Per Share -2.7
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get NewAmsterdam Pharma Company N.V. Earnings via APIs

  • Latest Release 2024-05-06
  • EPS/Forecast -0.6147

Get NewAmsterdam Pharma Company N.V. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get NewAmsterdam Pharma Company N.V. latest news via APIs

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage...

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

NewAmsterdam Pharma N.V. -- Company expects to report topline data in the first quarter of 2025 -- NAARDEN, The Netherlands and MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N...
Do you have any questions?
support@eodhistoricaldata.com